A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis

In biopsy-confirmed NAFLD, LiverMultiScan’s cT1, blood-based AST, GGT, and fasting glucose predicted significant fibrosis. The combined cTAG score (cT1+AST+glucose) outperformed individual markers, highlighting its utility for screening patients prior to biopsy to identify those suitable for NASH clinical trial enrolment.